RPM Healthcare publishes white paper on Medicare GLP-1 monitoring

RPM Healthcare released a white paper July 3 on the Medicare GLP-1 Bridge, arguing that access to weight-loss drugs for eligible Medicare Part D beneficiaries must be paired with monitoring. The report says older adults face added risks from discontinuation, dehydration, blood pressure changes, nutrition issues and muscle loss as the benefit begins July 1.

Why it matters: - The Medicare GLP-1 Bridge opens access to select GLP-1 medications for weight management for eligible Medicare Part D beneficiaries beginning July 1. - The policy gives qualifying older adults a $50 monthly copay through Dec. 31, 2027. - RPM Healthcare argues that access alone will not protect patients without monitoring for side effects, adherence and functional decline.

What happened: - RPM Healthcare released a white paper titled The Medicare GLP-1 Bridge: Why Monitoring Matters as Much as Access on July 3. - The Newark, New Jersey-based remote patient monitoring company said the report examines what the Medicare GLP-1 Bridge means for providers, patients and health system partners. - The white paper focuses on older adults who may now start GLP-1 therapy after facing financial barriers.

The details: - The report says many Medicare patients begin GLP-1 treatment while managing multiple chronic conditions, complex medication regimens and age-related risks. - The paper highlights frailty, hypotension, dehydration and muscle loss as key concerns. - The report says discontinuation is common among older adults and can lead to weight regain, care disruption and loss of clinical momentum. - RPM Healthcare says health systems should prepare for more GLP-1 starts by adding a clinical monitoring layer around medication access. - That approach includes RN care coach outreach, symptom triage, connected weight and blood pressure monitoring, nutrition guidance, protein intake support and reporting back to referring physicians. - Sarah Roberts, VP of Clinical Innovation at RPM Healthcare, said the first months of therapy can determine whether patients make sustainable progress or face preventable setbacks. - Roberts said patients need support with symptoms, hydration, blood pressure trends, nutrition and muscle preservation. - Roberts said GLP-1 therapy should be treated as an ongoing care model, not a one-time prescription. - RPM Healthcare says its internal cohort of 622 weight management patients showed 76.5% remained in active monitoring at 12 weeks. - Among patients still engaged at 12 weeks, average weight loss was 4.8 pounds. - At 24 weeks, the 329 patients still monitoring had average weight loss of 12.1 pounds. - The cohort included patients on GLP-1 therapy and patients using coaching alone.

Between the lines: - The white paper frames the Medicare GLP-1 Bridge as a test of whether health systems can turn drug access into durable care. - The report suggests organizations that pair access with monitoring may be better able to reduce early dropout and preserve patient function. - The emphasis on engagement, symptom response and blood pressure trends signals a broader shift from prescribing to longitudinal management.

What's next: - CMS will collect utilization data through the Bridge demonstration over the next 18 months. - RPM Healthcare says providers, payers and health system partners that can show sustained engagement and safer care coordination will be better positioned to influence the long-term model for Medicare GLP-1 care. - The full white paper is available here.

The bottom line: - RPM Healthcare is betting that the next phase of GLP-1 adoption for Medicare patients will be won by monitoring, not access alone.